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The targeted delivery of therapies to diseased tissues offers a safe opportunity to
achieve optimal efficacy while limiting systemic exposure. These considerations apply
to many disease indications but are especially relevant for rheumatoid arthritis (RA), as
RA is a systemic autoimmune disease which affects multiple joints. We have identified
an antibody that is specific to damaged arthritic cartilage (anti-ROS-CII) that can be
used to deliver treatments specifically to arthritic joints, yielding augmented efficacy in
experimental arthritis. In the current study, we demonstrate that scaffolds enriched with
bioactive payloads can be delivered precisely to an inflamed joint and achieve superior
efficacy outcomes consistent with the pharmacological properties of these payloads. As
a scaffold, we have used extracellular vesicles (EVs) prepared from human neutrophils
(PMNs), which possess intrinsic anti-inflammatory properties and the ability to penetrate
inflamed arthritic cartilage. EV fortified with anti-ROS-CII (EV/anti-ROS-CII) retained
anti-ROS-CII specificity and bound exclusively to the damaged cartilage. Following
systemic administration, EV/anti-ROS-CII (a) exhibited the ability to localize specifically
in the arthritic joint in vivo and (b) was able to specifically target single (viral IL-10 or
anti-TNF) or combined (viral IL-10 and anti-TNF) anti-inflammatory treatments to the
arthritic joint, which accelerated attenuation of clinical and synovial inflammation. Overall,
this study demonstrates the attainability of targeting a pro-resolving biological scaffold
to the arthritic joint. The potential of targeting scaffolds such as EV, nanoparticles, or
a combination thereof alongside combined therapeutics is paramount for designing
systemically administered broad-spectrum of anti-inflammatory treatments.
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INTRODUCTION
The development of anatomically targeted methods offers the
promise for effective therapy localized at the site of disease, which
optimizes pharmacological effect while minimizing systemic
exposure and ensuring increased safety. Rheumatoid arthritis
(RA) is the second most common form of arthritis in the
world, characterized by long-term inflammation in the joints
leading to cartilage and bone erosion and, eventually, joint
deformation. In the context of RA, targeted approaches offer the
promise of delivering highly effective disease-modifying agents
to the affected joints without the limitations of systemic toxicity.
Current therapies for the treatment of RA comprise synthetic or
biologic disease-modifying antirheumatic drugs (DMARDs) (1).
The development of small molecules and biologics has enabled
some degree of disease modification in RA patients. Nevertheless,
apart from a spectrum of adverse side effects, a significant
proportion of patients (∼40%) still have inadequate control of
their arthritis activity and do not enter remission (2, 3). Thus,
there remains a significant unmet need for improved treatment.
The current study investigates a novel form of drug
targeting using extracellular vesicles (EVs) as a cargo to
deliver single or multiple pharmacological payloads. Membrane-
derived microparticles/microvesicles, apoptotic bodies, and
exosomes are collectively known as EVs. EVs function in
cell-to-cell communication and carry microRNA (miRNA),
messenger RNA (mRNA), and hundreds of proteins and
lipids (4–6). They transmit these cargoes to different cells to
induce various changes in cell behavior, including transcription
and proliferation (7–9). EVs vary in their contents, and
in fact, the EV miRNA expression profile can serve as
a potential biomarker (10, 11). EVs appear to play key
roles in cancer progression and metastasis (12) and in the
normal maintenance and degeneration of musculoskeletal
tissues (13, 14).
An emerging approach of interest in the context of joint
disease is the utilization of neutrophil (PMN)-derived EV to
promote chondroprotective effects. In 2004, Gasser and Schifferli
showed that PMN EV exhibited anti-inflammatory properties
(15), and we reported that some of these are reliant to the
presence of phosphatidylserine and annexin A1 (16, 17). EVs
derived from PMN have been utilized as scaffolds for therapeutic
purposes through loading with alpha-2-macroglobulin and an
analogue of lipoxin A4 (18, 19). In a recent study, we uncovered
the chondroprotective effects of PMN EV in the K/BxN
serum transfer model of arthritis (20): these vesicles penetrated
into arthritic cartilage tissue to promote anabolic activities
yielding cartilage repair and protection (20). This concept has
been extended by a more recent study, where the EV/PMN
cell membrane was used to coat nanoparticles with reported
significant therapeutic efficacy in a collagen-induced human
transgenic mouse model of arthritis, with evident amelioration
of joint damage and suppression of the overall arthritis severity
(21). Importantly, all the above studies have been conducted
with local administration of the microstructures (20), which
places limitations on the effective translation of these findings
into clinical settings. In the present study, we have used an
antibody that is specific to damaged arthritic cartilage (anti-
ROS-CII) to develop an effective preparation of EV that, upon
systemic administration, specifically localizes EVs to the arthritic
joint. As a proof of concept, we have also utilized these novel
microstructures to deliver an anti-inflammatory payload—either
anti-TNFα or viral IL-10 or both.
In recent years, the development of small molecules and
biologics has greatly improved the treatment of RA; however, a
significant proportion of patients (∼40%) still have inadequate
control of their arthritis activity and do not enter remission.
Thus, there remains a significant unmet need for novel and
improved therapeutic strategies.
MATERIALS AND METHODS
Production of scFv and Fusion Antibodies
ScFv was produced as described (22). Transient transfection
of IgG and vIL-10 fusion antibodies was conducted in an
Expi293F system (Thermo Fisher Scientific). Cell supernatants
were purified by protein A sepharose column as described
(22). Purified antibodies were fluorescently labeled with
Cy5.5 fluorophore as per the manufacturer’s instructions
(Sigma GEPA15604).
Polymorphonuclear Leukocyte EV
Generation
Polymorphonuclear leukocytes (PMNs) were isolated from
healthy human volunteers by density gradient centrifugation
and then stimulated with recombinant human TNFα for 20min
at 37◦C to stimulate EV release (23). EVs were purified by
differential centrifugation as described (20). For fluorescent
observations, EVs were labeled using 50µM of thiol reactive
BODIPY FL maleimide or BODIPY TR dyes (Thermo Fisher
Scientific, B10250, and D6116, respectively). Collection of blood
samples from healthy human volunteers was approved by the
East London and The City Local Research Ethics Committee (Rec
Ref. 05/Q0603/34 ELCHA, London, UK). Informed consent was
received from participants prior to inclusion in the study.
ImageStreamX Analysis
All samples were acquired on an ImageStreamX MkII imaging
cytometer,×60 magnification; with low flow rate/high sensitivity
using INSPIRE software as described (23). Isolated EVs were
also analyzed using an NS300 Nanoparticle Tracker with a
488-nm scatter laser and high-sensitivity camera (Malvern
Instruments Ltd., Malvern, UK). For each sample, particle scatter
was recorded three times for 60 s each under flow conditions
(arbitrary speed 50) at camera level 14 and analysis threshold 5,
using the NTA 3.2 acquisition and analysis software.
Enrichment of EV With Antibodies
A “phospholipid cake” was created by adding 100µg of 1,2-
dioleoyl-sn-glycero-3-phospho-L-serine (phospholipid, Avanti
181PS) to a pear-shaped glass flask and evaporating the
chloroform solvent using a nitrogen stream. A solution
of fluorescent antibody and fluorescent EV was prepared,
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using 10µg of antibody for every 5 × 105 EVs (using 1.5–
2.5 × 106 vesicles in a 0.5ml reaction). The EV/antibody
solution was added to the phospholipid cake. The solution
was sonicated for 5min on a setting of three amplitude
microns using a Soniprep 150 ultrasonic disintegrator
with an exponential probe. Enriched EVs were purified by
differential centrifugation again as described to remove unbound
antibody (20). Samples were then appropriately prepared for
further experimentation.
Enzyme-Linked Immunosorbent Assay
(ELISA)
ELISA was performed by coating with 10µg/ml of collagen II or
ROS-modified collagen II (ROS-CII) or 10µg/ml of recombinant
mouse TNF (mTNF) as described (24). Antibody-enriched EVs
were added as primary antibody in the ELISA, as well as anti-
ROS-CII alone as a positive control and negative control antibody
(10µg per well). Binding was probed with anti-human IgG
1:1,000 dilution or anti-His Tag (Sigma Aldrich). TMB substrate
was finally added to detect binding. The reaction was stopped
using 50µl of 20% sulfuric acid, and absorbance was read at
450 nm. All washes were performed using PBS—without calcium
chloride and magnesium chloride.
Immunofluorescence Staining of Arthritis
Mouse Tissue
Sections of knee joints from antigen-induced arthritis (AIA)
mice were deparaffinized, dehydrated, and air-dried, followed
by fixation using 4% paraformaldehyde (PFA) in PBS. Antigen
retrieval was performed by incubations in 0.02% HCl for
15min at 37◦C and 0.02% HCl and 15 mg/ml of pepsin
solution for 45min at 37◦C. Tissue was then fixed again by
incubating in 4% PFA solution before incubating in 50mM of
ammonium chloride to quench autofluorescence. Non-specific
binding sites were blocked using 2.5% w/v powdered milk in
PBS—for 1 h at room temperature. Added to the samples and
incubated overnight in the dark at 4◦C was 5 × 105 BODIPY
FL-labeled EV alone, 10µg/ml of Cy5.5-labeled antibody-
enriched EV, or 10µg/ml of Cy5.5-labeled antibody alone.
The following day, slides were washed in PBS and mounted
using Fluoroshield with DAPI. Immunofluorescence staining
was imaged on an Olympus BX61 microscope equipped with a
Hamamatsu Orca-R2 digital camera. Images were acquired using
Cell P/Sense software.
In vivo Imaging
AIA was performed on female, 10-week-old C57BL/6 mice as
described (25). Inflammation was stimulated in only one knee,
with contralateral knees acting as controls. On day 22 and 24 h
after stimulating inflammation in the right knee joint, mice
were intravenously administered fluorescently labeled anti-ROS-
CII (Cy5.5)-enriched EV (BODIPY TR) or EV alone (600,000
EVs for each injection). For IVIS Optical Imaging, mice were
biofluorescently imaged as described (26). All experimental
protocols were performed in compliance with the UK Animals
(Scientific Procedures) Act 1986 regulations for the handling
and use of laboratory animals (Home Office project license PPL
no. 70/8264).
Treated Knee Histology
For paraffin embedding, knee joints were harvested and
incubated in 4% neutral buffered formalin followed by
decalcification with EDTA for 3 weeks and embedding in
paraffin wax. Knees were sectioned at 5µM thickness with a
minimum of two sections per knee used for scoring. Safranin
O staining (Sigma, S8884) and hematoxylin-and-eosin (H&E,
Sigma Aldrich, 102439) staining were performed as in (27). For
collagen type X and anti-ROS-CII, immunostaining was done as
above (28).
Confocal Microscopy
Cryosectioning was done as described (29). Harvested knee
joints were snap-frozen in OCT medium and followed by 17-
µM-thick tissue sections. Knee cryosections were dried and
mounted using a Fluoroshield mounting medium (Sigma, F6182)
before being imaged on a Leica SP8 confocal microscope
with the use of a 20× water-dipping objective. Images were
attained with the use of sequential scanning of different
channels at an XY resolution of 1,024 × 600 with a speed
of 700Hz, zoom factor of 1.28, and line average of 4.
Images were analyzed with the image processing software
IMARIS. Fluorescent localization of treatment was quantified
using Image J/Fiji software. Cartilage regions of interest were
drawn, and integrated density of both BODIPY TR and Cy5.5
was measured.
Quantitative Real-Time Polymerase Chain
Reaction
Total RNA was extracted from snap-frozen knee joints using
the TRIzol method, as previously described (30). Reverse
transcription of 1µg of total RNA was done using a High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) with random primers and following manufacturer’s
protocol. Real-time PCR was carried out using power SYBR
Green Master Mix in a real-time PCR system (Applied
Biosystems Inc.). Data are expressed as relative units calculated
by 2−11Ct by normalization relative to RPL32 and to fold change
over naive control samples.
Statistics
Statistical analysis was performed using GraphPad Prism 8
software and R 3.5.2. We have used several statistical measures
appropriate to the experiments. We performed a mixed-model
ANOVA (when the data were collected and analyzed together),
allowing for a random intercept and slope of day or a two-
way repeated-measures ANOVAwith Holm–Sidak post-hoc, with
Tukey post-hoc tests comparing the main effects of treatment.
We also performed separate Kruskal–Wallis with Dunn post-
hoc tests. For the localization experiment, we used R to model
the Cy5.5 and BODIPY TR data with a separate three-way
mixed-model ANOVA, using time, treatment, and knee as
independent variables.
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FIGURE 1 | EV/anti-ROS-CII in vitro characterization. (A) Anti-ROS-CII antibodies were loaded onto PMN-derived EV (EV/anti-ROS-CII) through a process of energy
dissemination and fusion with lipid vesicles, as outlined in the schematic created with BioRender. (B) Incorporation of anti-ROS-CII antibodies upon EV was assessed
by ImageStreamX. Representative image of EV (B.1) and EV enriched with anti-ROS-CII antibody (B.2) obtained from the ImageStream analysis, with bright field
shown in channels 1 and 9, Ch01, and Ch09; side scatter in channel 12, Ch12; EV fluorescence (BODIPY) in channel 2, Ch02; and antibody fluorescence (Cy5.5) in
channel 11, Ch11. Of the EV population, 89% was positive for the anti-ROS-CII fluorescence. (C) Antibody functionality after incorporation upon EV was tested by
ELISA. Binding characteristics to native collagen type II (CII) and ROS modified CII (CII modified by ribose; Gly-CII and HOCl; HOCl-CII) were determined. Both pellet
and removed supernatant were analyzed to determine the relative antibody reactivity loaded upon EV, as compared to the unbound. Data are shown as mean ± SEM,
n = 3. There was a significant difference between reactivity to native CII vs. ROS-CII (Gly-CII and HOCl-CII, p < 0.001), but no main effect between pellet and
supernatant (p > 0.05). (D) Binding specificity was also determined using sections from mouse antigen-induced arthritis knee tissue taken 7 days after induction.
Immunofluorescence of EV (BODIPY FL) and EV enriched with either anti-ROS-CII (EV/anti-ROS-CII, Cy5.5) or control antibody specific to hen egg lysozyme
(EV/anti-HEL) binding within the arthritic cartilage was assessed. Specific binding to articular cartilage (AC) was observed by anti-ROS-CII and EV/anti-ROS-CII but not
with EV or EV/anti-HEL. SB, subchondral bone; BM, bone marrow. Scale bar = 50µm.
RESULTS
Antibodies Incorporated Onto EV Retain
Binding Specificity
EVs were isolated from PMN and analyzed for size
and concentration by nanoparticle tracker analysis
(Supplementary Figures 1A–C). Antibodies to ROS-CII
were incorporated onto EV using aqueous energy dissemination,
in which sonication results in the production of liposomes,
which entrap the antibody while simultaneously integrating
within the vesicle membrane (Figure 1A). For monitoring
antibody incorporation, EV and anti-ROS-CII were fluorescently
labeled with BODIPY FL and Cy5.5, respectively, and analyzed
using ImageStreamX. The EV population was gated through
their characteristic low side scatter and positive BODIPY
FL fluorescence and then probed for antibody fluorescence
positivity (Cy5.5). Of the EV event population, 89% were positive
for the anti-ROS-CII fluorescence, with a mean incorporation
of 87% out of repeated and distinct preparations. ImageStream
analysis of EV alone (B1) compare to EV enriched with anti-
ROS-CII antibody (B2) showed that both EV and enriched
EV are round with no structural disturbance (Figure 1B,
Supplementary Figures 1E,F).
Following incorporation, EVs were pelleted and resuspended,
and supernatants were removed to take any unincorporated
antibody. Both resuspended pellet and supernatant were
subjected to ELISA to determine presence of anti-ROS-CII in
the fortified EV (EV/anti-ROS-CII). Specific binding of EV/anti-
ROS-CII to ROS-CII was quantified, and a similar signal
was detected in the supernatant, indicating ∼50% antibody
incorporation on the EV (Figure 1C). Immunofluorescence
analysis was conducted to confirm the specific binding of
EV/anti-ROS-CII to arthritic cartilage. Sections incubated with
EV alone or EV fortified with isotype control antibody
specific to hen egg lysozyme (EV/anti-HEL) exhibited minimal
fluorescence. As expected, robust staining of damaged cartilage
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FIGURE 2 | In vivo localization of EV/anti-ROS-CII. Antigen-induced arthritis was induced in the right knee of female C57BL/6 mice. One day after the stimulation of
inflammation in the right knee, mice were injected with 6 × 105 i.v. of either EV alone or EV/anti-ROS-CII or EV/anti-HEL. Localization of EV in the arthritic and
contralateral knees was assessed by IVIS Optical Imaging. (A) A specific localization of EV/anti-ROS-CII in the arthritic knee was observed, with peak localization at
18 h post-administration in both the Cy5.5 and BODIPY TR channels, indicating antibody and EV co-localization (p = 0.009 for Cy5.5 fluorescence and p = 0.034 for
BODIPY TR). (B) Knees and organs were imaged by IVIS in the BODIPY TR channel ex vivo at the end point of the experiment (48 h). Mice injected with
EV/anti-ROS-CII showed higher retention of fluorescence signal within the arthritic knees compared to those treated with EV alone and EV/anti-HEL-treated samples
(p < 0.05). Data are shown as mean ± SEM, n = 3 or 4 mice per group. Three-way mixed-model ANOVA was performed, with time, treatment, and knee as
independent variables (the intercept and slopes of time and knee were allowed to vary for each mouse) with Holm–Sidak post-hoc tests of simple effects.
was observed using anti-ROS-CII. Importantly, following anti-
ROS-CII incorporation onto EV, enhanced EV fluorescence was
observed specifically within the arthritic cartilage (Figure 1D).
Thus, we incorporated anti-ROS-CII antibody on EV, and these
new structures display specific binding, which is augmented
when compared to application of the single tool.
EV Fortified With Antibodies to ROS-CII
Localize to Arthritic Joints in vivo
A mouse model of AIA was utilized to demonstrate joint-
specific targeting of these scaffolds in vivo. Using IVIS optical
imaging, we could visualize accumulation of BODIPY TR-labeled
EV and Cy5.5-labeled antibody to the arthritic knee joint as
compared with the healthy contralateral control knee. This
specific localization of EV/anti-ROS-CII in the arthritic knee
peaked at 18 h post-administration as quantified for both the
Cy5.5 and BODIPYTR channels, indicating co-localization of the
antibody with the EV (Figure 2A). A significantly lower signal
was detected in the contralateral control knee as seen for both
BODIPY TR fluorescence (p = 0.034) and Cy5.5 fluorescence
(p = 0.009) at 18 h. Notably, the BODIPY TR signal for EV
alone dropped dramatically from the early time points, indicating
clearance or loss of retention of the vesicles within the joint tissue.
At the end-point of the experiment (48 h), knees and organs
were harvested and imaged ex vivo. Mice injected with EV/anti-
ROS-CII showed higher retention of EV fluorescence signal
within the arthritic knees compared to EV alone (p < 0.05) and
EV/anti-HEL (p < 0.05, Figure 2B). No off-target signal was
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FIGURE 3 | In vitro characterization of EV/anti-ROS-CII enriched with vIL10 and anti-mTNF. Anti-ROS-CII-vIL10 and anti-mTNF were loaded upon PMN EV through
fusion with lipid vesicles. (A) Incorporation of anti-ROS-CII-vIL10 labeled with AF488 and anti-mTNF labeled with Cy5.5 upon EV was validated by ImageStreamX.
Incorporation of both antibodies resulted in 78% of EV staining double positive for both the anti-ROS-CII-vIL10 antibody and the anti-mTNF antibody. (B) ELISA plates
were coated with recombinant mTNF or ROS-CII to test the binding specificity of the antibodies after EV incorporation. Both anti-ROS-CII and anti-mTNF embedded
on the EV retained their specific binding to ROS-CII and mTNF, respectively. (C) The efficacy of anti-mTNF-enriched EV to inhibit mouse recombinant TNF-induced cell
death in L929 cells was tested by MTT assay. Inhibition of cell death was evident only in EV/anti-mTNF and EV/anti-ROS-CII&mTNF/vIL-10. L929 cell death induced
by human TNF (hTNF) was not inhibited by anti-mTNF. Data shown as mean ± SEM of n = 3, p < 0.0001. Data were analyzed by one-way ANOVA with Tukey
post-hoc test.
detected systemically, except for some signal in the liver and
kidney, likely reflecting antibody/EV clearance (Figure 2B).
Enrichment of EV With Multiple
Therapeutics
EVs were fortified with either or both AF488-labeled anti-ROS-
CII/vIL-10 and Cy5.5-labeled anti-mouse TNFα (anti-mTNF).
Fortified EVs were analyzed for size by nanoparticle tracker
analysis (Supplementary Figure 1D). ImageStreamX confirmed
the presence of both proteins upon the EV following aqueous
energy dissemination with ∼80% EVs being positive for
both antibody fluorophores (Figure 3A). EVs enriched with
multiple bioactive payloads are round with no structural
disturbance (Supplementary Figure 1F). Specific binding of
antibody-enriched EV to ROS-CII and mTNF was determined
using ELISA. Positive antibody controls (anti-ROS-CII-vIL10
and anti-mTNF) exhibited robust binding to their respective
antigens. Importantly, EV loaded with both anti-ROS-CII-vIL-
10 and anti-mouse TNFα antibodies retained binding to both
murine TNF (mTNF) and ROS-CII (Figure 3B), indicating
that that vesicle was amenable to be loaded with more than
one therapeutic agent. Of importance is that not only can
the EV afford a scaffold of inert anti-inflammatory properties,
but it can also cargo bioactive payloads. To address this, a
functional bioassay for mTNF was performed using L929 cell
survival. Following application of a lethal concentration of
murine recombinant TNF, soluble anti-mTNF, but not EV alone,
inhibited cell death in a concentration-dependent manner. In
contrast, vesicles enriched with anti-mTNF antibody retained
the ability to inhibit cell death similarly to anti-mTNF antibody
alone. Anti-mTNF antibody was ineffective when recombinant
human TNF was used in the cell culture medium instead of
murine TNF (Figure 3C), indicating species specificity.
EV/Anti-ROS-CII Loaded With
Therapeutics Accelerates Resolution of
Joint Inflammation
To test the efficacy of the EV to cargo in vivo, AIA mice were
treated intravenously with EV/anti-ROS-CII-vIL-10 (on days 1
and 3) post-induction of arthritis. This EV/anti-ROS-CII-vIL-
10 treatment afforded a higher degree of reduction in knee
swelling (p = 0.028) and was more effective than EV enriched
with vIL-10 fused to isotype control antibody—that is, specific to
hen egg lysozyme (anti-HEL-vIL-10; Figure 4A). Similarly, while
EV/anti-mTNF was associated with modest attenuation of joint
inflammation similar to EV alone (p = 0.216), administration
of EV/anti-ROS-CII&mTNF enhanced the reduction in arthritic
knee swelling (p= 0.013).
At end-point, mouse joints were harvested, snap-frozen, and
sectioned prior to imaging to visualize EV and anti-ROS-CII-
vIL-10 retention in the arthritic cartilage (Figure 4B). Both
EV fluorescence (BODIPY TR) and anti-ROS-CII fluorescence
(Cy5.5) could be detected by confocal microscopy within the
joint cartilage of mice treated with EV/anti-ROS-CII-vIL-10
(yellow overlay; Figure 4B, b.2). This was exclusive to the
ipsilateral, inflamed knee, with cartilage treated with control
EV/anti-HEL-vIL10 showing no specific fluorescent localization
(Figure 4B, b.4). Quantification of the EV and antibody
fluorescence in the cartilage of AIA and contralateral joints
confirmed this (Figure 4C). Importantly, knee swelling in AIA
mice treated with EV/anti-ROS-CII&mTNF/vIL-10 combination
therapy resolved significantly faster, returning to baseline levels
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FIGURE 4 | Treatment of antigen-induced arthritis with EV enriched with monotherapy. Antigen-induced arthritis was induced in the right knee of female C57BL/6
mice. On day 1 and 3, mice were injected with 6 × 105 i.v. of EV, EV/anti-ROS-CII-vIL-10, EV/anti-HEL-vIL-10, EV/anti-mTNF, EV/anti-ROS-CII&mTNF, or PBS vehicle
control. (A) Treatment points are indicated by black arrows. Knee swelling was quantified daily using digital calipers. Data are expressed as mean ± SEM, n = 5–8
mice per treatment group and n = 3–6 mice for vehicle group. Top panel were analyzed by two-way repeated-measures ANOVA (with time and treatment as
independent variables) with Holm–Sidak post-hoc tests. As the data were all normalized to day 1, day 1 was omitted from the analysis (as the values are all 100).
A significant difference between vehicle and EV/anti-ROS-CII-vIL-10 (p = 0.028) was observed. Lower panels show analysis by a mixed-model ANOVA, allowing for a
random intercept and slope of day (which was entered as a continuous variable), with treatment as a fixed factor. There were no significant differences between the
vehicle group and the EV alone (p = 0.216) or EV/anti-TNF (p = 0.216). A significant difference between vehicle and EV/anti-ROS&mTNF (p = 0.013) was observed.
(B) Knees from EV/anti-ROS-CII-vIL10- and EV/anti-HEL-vIL-10-treated mice were sectioned and imaged by confocal microscopy to identify EV/antibody localization;
bright-field images were also taken for reference (b.1, b.3). EV/anti-ROS-CII-vIL10 AIA knee (b.1, b.2); EV/anti-HEL-vIL-10 AIA knee (b.3, b.4). Red fluorescence:
BODIPY TR (EV); cyan fluorescence: Cy5.5 (anti-ROS-CII); yellow fluorescence in b.2 indicates co-localization of anti-ROS-CII antibody and EV. Scale bar = 40µm.
(C) Quantification of BODIPY TR and Cy5.5 fluorescence in the cartilage of knee joint sections. 1: EV/anti-ROS-CII-vIL-10 AIA knee, 2: EV/anti-ROS-CII-vIL-10
contralateral knee, 3: EV/anti-HEL-vIL-10 AIA knee, and 4: EV/anti-HEL-vIL-10 contralateral knee.
compared to EV alone (p = 0.001). Treatment with single-
cargo EVs, anti-ROS-CII-vIL-10 therapy, also accelerates edema
reduction compared to vehicle (p = 0.049) but was slower than
treatment with EV/anti-ROS-CII&mTNF/vIL-10 (Figure 5A).
Comparative Gene Expression Analysis in
the Knee Joints
To elucidate potential mechanisms behind the anti-arthritic
effects of fortified EV, gene expression was measured in the
arthritic joints at day 7. Mice treated with EV/anti-ROS-CII-
vIL-10 or EV/anti-ROS-CII&mTNF/vIL-10 exhibited reduced
expression of (a) pro-inflammatory gene products like Tnf, Il-
1β , and Il-6 and (b) Mmp13 and Adamts5 genes involved
in cartilage degradation. In contrast, increased expression of
(i) anti-inflammatory cytokine gene product Il-4 and, to a
lesser extent, Il-10 and (ii) Sox9, Acan, and Col2a1 genes,
responsible for cartilage maintenance and/or regeneration, was
observed (Figure 5B).
Histological Analysis of the Knee Joints
Histopathology scoring was performed on safranin O- and
H&E-stained slides, while immunohistochemistry analyses
were conducted for anti-ROS-CII and anti-collagen type X
antibodies. An example of each detailed scoring is shown
in Supplementary Figure 2. Compared to vehicle and EV
comparator groups, EV delivery of IL-10 or anti-TNFα was
associated with reduced joint inflammation and chondrocyte
death. While we did not observe a significant difference in
cartilage matrix integrity and safranin O staining, we did
observe a reduction in pannus formation, synovial fluid immune
cells, chondrocyte death, and bone marrow involvement. This
cumulative analysis of synovial inflammation and chondrocyte
death is displayed in Supplementary Figure 2. In the non-treated
control group, there was no resolution of synovial inflammation.
In the EV/anti-ROS-CII&mTNF/vIL-10 group of mice, clinical
signs of arthropathy were abolished over time with associated
clear indications of a reduction in the histological signs of joint
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FIGURE 5 | Treatment of antigen-induced arthritis with EV fortified with combined treatment. Antigen-induced arthritis was induced in the right knee of female
C57BL/6 mice. On day 1 and 3, mice were injected with 6 × 105 i.v. of EV alone, EV/anti-ROS-CII-vIL-10, EV/anti-ROS-CII&mTNF/vIL-10, or vehicle. (A) Knee
swelling was monitored using digital calipers. Data are expressed as mean ± SEM, n = 5 mice per treatment group (n = 3 mice for the vehicle group). Data were
analyzed using a mixed-model ANOVA, allowing for a random intercept and slope of day (which was entered as a continuous variable), with treatment as a fixed factor.
There were significant main effects of treatment and day, and Holm–Sidak post-hoc tests comparing the overall knee width of each treatment group to the vehicle
group indicated lower knee widths for EV/anti-ROS-CII-vIL-10 (p = 0.0499) and EV/anti-ROS-CII-vIL-10/anti-TNF (p = 0.001) treatment groups (control groups are
the same as in Figure 4A, bottom panel). There were no significant differences between the vehicle group and the EV alone (p = 0.216). (B) Local gene expression
was measured by quantitative PCR (qPCR) in the arthritic joints at day 7. Data were normalized over the RPL32 housekeeping gene and are expressed as fold change
over control knee joints from naive mice, with average expression levels represented using a heat map (n = 3 mice per group).
inflammation. In some mice, we observed complete resolution
(Figure 6A), but we mostly observed a range of histological
improvement. The data indicated that knee swelling changes
preceded signs of histological improvement. Compared to single
treatments, the double-cargo EVs afforded a higher degree of
protection on a variety of histological markers, with particular
efficacy in reducing chondrocyte death. Immunostaining with
anti-ROS-CII revealed presence of areas of mixed residual
damaged cartilage and repair—which corresponded with
regions of chondrocyte hypertrophy—indicated by staining with
antibody to collagen type X (Figure 6B).
DISCUSSION
In this study, we describe a proof-of-concept study using
a specific anti-ROS-CII antibody delivery system affording
anatomically specific targeting of an EV and EV-packaged
bioactive payload to the inflamed joint. Our principal aims
were to demonstrate fidelity of anatomical targeting using this
technology, to establish some key pharmacokinetic outcomes,
and to show that targeting bioactive payloads following systemic
administration was associated with a therapeutic benefit.
Herein, we have harnessed two distinct biological features:
one represented by a targeting antibody specific for arthritic
cartilage (anti-ROS-CII) and the other being packaged reparative
information delivered by PMN EV. Moreover, we constructed
and validated a new therapeutic tool that combines these benefits.
Our aim was to define whether selective targeting could achieve
an improved pharmacodynamic profile. Indeed, using a model
of joint arthritis in mice, we could demonstrate that enriching
EV with anti-ROS-CII (a) targets EV to arthritic joints following
intravenous injection; (b) enhances binding and retention of EV
within the arthritic cartilage; and (c) accelerates the attenuation
of clinical and synovial inflammation following fortification with
anti-inflammatory drugs.
Plasma membrane-shed vesicles complement intercellular
communication driven by soluble mediators, like cytokines,
autacoids, and hormones. PMN EVs hold powerful anti-
inflammatory and pro-resolving qualities and can penetrate
>100µm deep into the cartilage matrix (15). Moreover,
the inherent anti-inflammatory effect exhibited by PMN EV
has been exploited by loading additional proteins or lipid
mediators, to enhance innate immune cell function to expedite
resolution responses (18, 19). A recent study has gone a step
further and fused PMN membranes onto polymeric cores,
showing that these EV/polymeric hybrids can neutralize pro-
inflammatory cytokines, suppress synovial inflammation, and
penetrate cartilage while providing chondroprotection against
joint damage. The EV/polymeric hybrid core demonstrated a
significant therapeutic effect in a mouse model of collagen-
induced arthritis and in a human transgenic mouse model of
arthritis (21). Nevertheless, efficacy was observed only following
local administration, and similar observations were made by us
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FIGURE 6 | Histological analysis of excised knee joints. Histopathology analysis of knee sections revealed a spectrum of anti-inflammatory responses. (A) Safranin O
staining of example knees comparing vehicle to treatment groups which were improved to various degrees. We observed improved histological arthropathy phenotype
with mice treated with EV enriched with both vIL10 and anti-TNFα which in some mice as shown in this example resemble naive phenotype. Safranin O staining of
cartilage from non-treated AIA knee (vehicle) displayed weaker staining and abundant chondrocyte death. The cartilage from healthy control animals was smooth, with
clear strong staining with safranin O. In the EV-treated knee, we observed areas of weak safranin O staining within the cartilage layers. (B) Examples from other groups
of sections within the central region of the knee were stained with hematoxylin and eosin (H&E), safranin O, anti-ROS-CII, and anti-collagen type X. Example images
show corresponding regions within the same diseased knee in the anti-ROS-CII&mTNF/vIL-10 treatment group. Chondrocyte death within the cartilage can be seen
(black arrows). The presence of damaged cartilage is stained by anti-ROS-CII (oxidative post-translationally modified collagen type II neo-epitope, red). These areas
corresponded with regions of chondrocyte hypertrophy indicated by staining with antibody to collagen type X (anti-CX, yellow). Lines define the boundaries of the
articular cartilage (AC).
too with natural EVs (20, 23). Obviously, a delivery modality
which can be introduced systemically has greater flexibility for
translational studies in humans.
To target EVs to the arthritic joint following systemic
treatment, we harness our own discovery of an antibody
to disease-modified CII. Indeed, inflammation leads to the
generation and release of large amounts of enzymes and reactive
oxidants (e.g., O2−, NO·, H2O2, or HOCl) which provoke
post-translational modification of the extracellular matrix and
other proteins exposed on the cellular plasma membrane. We
have produced and characterized an antibody that is specific
to CII post-translationally modified by oxidants (anti-ROS-
CII). This unique antibody has been validated in a series of
studies demonstrating strong immunostaining on arthritic but
not healthy cartilage, specific targeting to arthritic joint in vivo,
and attenuation of knee inflammation by drug targeted by anti-
ROS-CII (28, 31). Once grafted onto EV, the anti-ROS-CII
antibody acted as an arthritic cartilage-specific navigator, leading
to an accumulation of EV selectively to arthritic joints with
a peak at 18 h post-i.v. injection (Figure 2). This was in clear
contrast to EV alone that could be found in the tissue (probably
through passive extravasation or other unknown mechanisms
of trafficking) but evidently were not retained in the joint since
they were almost absent at 18 h post-injection. EV/anti-ROS-CII
signal was not detected in the heart, lungs, or spleen, but some
degree of clearance through the liver and kidney was detected,
as expected for vesicles that use the reticulum–endoplasmic
pathway for elimination, a path used also by apoptotic bodies and
other foreign bodies.
This favorable pharmacokinetic profile translated into local
pharmacodynamic improvement, consistent with a model of
depot release of payload into the local joint microenvironment,
thus raising the possibility that targeted EV could be used to
cargo specific therapies. This technology would not only have
the potential to augment efficacy but could and should also
markedly improve safety by limiting systemic exposure. A major
drawback in the use of biologics is not only their costs and
proportion of patient unresponsiveness (32); there is also a major
medical issue that is the induction of immune suppression with
re-emergence of silent and symbiotic infections, on top of host-
to-drug antibody generation (33). As such, there is an urgent
need to harness the positive properties of biologics while avoiding
the burden of important side effects. We reasoned that our
EV/anti-ROS-CII technology could be of use here and have tested
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the pharmacodynamic improvement of targeted anti-mTNF and
vIL-10 and provide proof of concept for further optimization
and development.
EV enriched with anti-ROS-CII fused to an anti-inflammatory
cytokine, vIL-10, or anti-mTNF accelerated reduction of knee
swelling compared to EV loaded with control anti-hen egg
lysozyme fused to vIL-10 or with anti-TNF only (Figure 4).
In a separate set of experiments, we enriched the EV with
two therapeutic agents: the anti-inflammatory cytokine, vIL-10,
and a pro-inflammatory cytokine blocker, and the anti-mTNF
antibody. Combined EV/anti-ROS-CII targeted treatment of
anti-mTNF and vIL-10 resulted in accelerated resolution of knee
swelling, as compared to a single vIL-10 treatment (Figure 5A).
This clinical outcome is supported by evidence of improvement
in synovial histopathology. The knee swelling effects, however,
were more marked and less variable than the efficacy effects
observed histologically—a differential entirely consistent with
the differing kinetics of resolution of knee edema compared
to resolution of the cellular inflammatory response. In terms
of anatomical localization within the knee capsule, in some
of the sections, we observed residual staining with anti-ROS-
CII within the chondrocytes localized in the intermediate and
deep cartilage zones. Interestingly, in the same region, there
appeared to be enhanced staining on hypertrophic chondrocytes,
an observation which related to retraction of the tide mark
as evidenced by safranin O and increased collagen X staining.
These results offer presumptive evidence for a chondroprotective
effect. Further studies in a more chronic setting are required to
delineate the exact phenotype of this response and to establish
the relationship between enhanced staining of this putative
immature chondrocyte and the dynamics of cartilage repair.
To gain some mechanistic insight for the added value
provided by this new technology, we monitored a variety
of gene products by qPCR analysis. The results indicated
a degree of cartilage remodeling and repair which was
incited by the combined (EV/anti-ROS-CII&mTNF/vIL-10)
therapy over and above that attained by the single therapeutic
approaches (EV alone or anti-ROS-CII/vIL-10). Augmented
expression of anabolic genes like Acan, Sox9, and Col2a2
was quantified following EV/anti-ROS-CII&mTNF/vIL-
10 with lower degradative genes Mmp13 and Adamts5.
The anabolic effect can be due to inherent variety of EV
mediators including annexin A1 (20) and/or pro-resolving
lipid mediators like resolvin D1 (34). This genomic response
complemented the morphological evidence that there was
reduced chondrocyte loss. The ability of EV to penetrate into
the cartilage plate gives confidence that chondroprotection
within the superficial and intermediate cartilage zones is
a viable therapeutic goal (20). These remodeling effects of
EV/anti-ROS-CII&mTNF/vIL-10 were complemented by
different expressions of inflammatory gene products: pro-
inflammatory Tnf, Il-1β , and Il-6 expression was lower, while
anti-inflammatory Il-4 was higher in treated mice. These
readouts were in partial agreement with macroscopic and
histological analyses and could underpin some of the effects
on cartilage, considering the central role that IL-1β plays in
chondrocyte reactivity (35).
Histopathology analysis of knee sections revealed an
important outcome with respect to anti-ROS-CII binding,
which was detected in the lacunae of a range of chondrocyte
forms and was localized in the intermediate and deep cartilage.
Interestingly, there appeared to be enhanced staining on
hypertrophic chondrocytes, an observation which related to
retraction of the tide mark as evidenced by safranin O and
increased collagen X staining. There was a degree of discrepancy
between the diverse profiles of histopathology compared to
unique observed knee edema resolution: these differences
probably reflect differences in the resolution of the vascular
response compared to a slower kinetics for resolution of cellular
inflammation and synovial hypercellularity. The totality of the
genomic, clinical, and histological outputs support the concept
of a viable anti-inflammatory signal originating from the targeted
cartilage plate. Obviously, this model format was designed to
demonstrate proof of concept of active payload delivery and not
optimized or powered for the differing kinetics of gene, edema,
synovitis, and cartilage attenuation and remodeling. A key focus
of further work will be to explore this mechanism in the context
of chondroprotection.
In summary, our new technology enables a simple, cost-
effective, and reproducible approach for enriching EV with
a variety of therapeutics, offering anatomical targeting of
anti-inflammatory payloads to an inflamed joint. We have
demonstrated a concordance between effective delivery and key
efficacy outcomes and gained insight into the potential for
more optimized delivery modalities to deliver chondroprotective
effects in a more chronic setting. The linchpin of our therapeutic
strategy is the potential to mix therapeutics that are loaded
upon the EV. With a personalized medicine approach, alongside
the successful systemic targeting of therapeutics directly to the
arthritic joint, greater treatment efficacy with fewer side effects
can be achieved.
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